Tool development for prediction of pIC50 values from the IC50 values - A pIC50 value calculator

Current Trends in Biotechnology and Pharmacy

Volumn 5, Issue 2, 2011, Pages 1104-1109

  Selvaraj, Chandrabose ^a   Tripathi, Sunil Kumar ^a   Reddy, Karnati Konda ^a   Singh, Sanjeev Kumar ^a  

^a ALAGAPPA UNIVERSITY   (India)

Author keywords

IC50; Micromolar; Nanomolar; piC50; QSAR

Indexed keywords

ALGORITHM; ARTICLE; BIOLOGICAL ACTIVITY; CALCULATOR; COMPUTER LANGUAGE; COMPUTER PROGRAM; IC 50; MATHEMATICAL COMPUTING; MOLECULAR MODEL; PREDICTION;

EID: 79953761696     PISSN: 09738916     EISSN: 22307303     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Tropsha, A and Golbraikh, A., (2007) Predictive QSAR modeling workflow, model applicability domains, and virtual screening. Curr Pharm Des. 13:3494-504.
2. Dixon, S.L., Smondyrev, A.M., Knoll, E.H., Rao, S.N., Shaw, D.E and Friesner, R.A., (2006) PHASE: a new engine for pharmacophore perception, 3D QSAR model development, and 3D database screening: 1. Methodology and preliminary results. J Comput Aided Mol Des. 20:647-71.
3. Lyles, R. H., Poindexter, C., Evans, A., Brown, M. and Carlton R. Cooper. (2008). Nonlinear model-based estimates of IC50 for studies involving continuous therapeutic dose-response data. Contemporary Clinical Trials, 29: 878-886.
4. Yung-Chi, C. and Prusoff, W. H. (1973). Relationship between the inhibition constant (KI) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical Pharmacology. 22: 3098-3108.
5. Whitebread, S., Hamon J., Bojanic, D. and Urban, L. (2005). Keynote review: In vitro safety pharmacology profiling: an essential tool for successful drug development. Drug Discovery Today, 10: 1421-1433.
6. Joshi, K.A., Patil D.D. and Gejji S.P. (2009). Molecular electrostatic potentials in aromatic substituted 4-hydroxyquino-2-lones: Glycine/ NMDA receptor antagonists. Journal of Molecular Modeling. 15: 383-390.
7. Toutain, P-L. (2002). Pharmacokinetic/ pharmacodynamic integration in drug development and dosage-regimen optimization for veterinary medicine. The AAPS Journal. 4: 160-188.
8. Stahl, M., Guba, W. and Kansy, M. (2006). Integrating molecular design resources within modern drug discovery research: the Roche experience. Drug Discovery Today, 11:326-333.
9. Dessalew, N. and Singh S.K. (2008). 3D-QSAR CoMFA and CoMSIA study on Benzodipyrazoles as Cyclin Dependent Kinase 2 Inhibitors. Medicinal Chemistry. 4: 313-321.
10. Lu, X.Y., Chen, Y.D., Sun, N.Y., Jiang, Y.J. and You, Q.D. (2010). Molecular-docking-guided 3D-QSAR studies of substituted isoquinoline-1,3-(2H,4H)-diones as cyclin-dependent kinase 4 (CDK4) inhibitors. Journal of Molecular Modeling. 16: 163-173.
11. Herve, F., Caron, G., Duche, J-C., Gaillard, P., Abd Rahman, N., Tsantili-Kakoulidou, A., Carrupt, P.A., Dathis, P., Tillement, J.P. and Testa, B. (1998). Ligand Specificity of the Genetic Variants of Human α1-Acid Glycoprotein: Generation of a Three-Dimensional Quantitative Structure-Activity Relationship Model for Drug Binding to the A Variant. Molecular Pharmacology. 54: 129-138.
12. Gianazza, L., Eberini, I., Villa, P., Fratelli, M., Pinna, C., Wait, R., Gemeiner, M. and Miller, I. (2002). Monitoring the effects of drug treatment in rat models of disease by serum protein analysis. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 771: 107-130.
13. Singh, S.K., Dessalew, N and Bharatam, P.V. (2006). 3D-QSAR CoMFA study on indenopyrazole derivatives as cyclin dependent kinase 4 (CDK4) and cyclin dependent kinase 2 (CDK2) inhibitors. European Journal of Medicinal Chemistry, 41: 1310-1319.
14. Kulkarni, R.G., Srivani, P., Achaiah G. and Sastry, G. N. (2007). Strategies to design pyrazolyl urea derivatives for p38 kinase inhibition: a molecular modeling study. Journal of Computer-Aided Molecular Design, 21(4): 155-166.
15. Chung, J.Y., Chung, H. W., Cho, S. J., Hah, J.M. and Cho, A. E. (2010). QM/MM based 3D QSAR models for potent B-Raf inhibitors. Journal of Computer-Aided Molecular Design, 24(5): 385-397.
16. th edition), John Wiley, USA.
17. nd edition), McGraw-Hill, USA.
18. ++dependent protein kinase. Biochemical and Biophysical Research Communications, 135: 397-402.
19. Dessalew, N., Bharatam, P. and Singh, S.K. (2007), 3D-QSAR CoMFA Study on Aminothiazole Derivatives as Cyclin-Dependent Kinase 2 Inhibitors. QSAR & Combinatorial Science, 26: 85-91.
20. Raj, N. Misra., Hai-yun Xiao., Kyoung S. Kim., Songfeng Lu., Wen-Ching Han., Stephanie A. Barbosa., John T. Hunt., David B. Rawlins., Weifang Shan., Syed Z. Ahmed., Ligang Qian., Bang-Chi Chen., Rulin Zhao., Mark S. Bednarz., Kristen A. Kellar., Janet G. Mulheron., Roberta Batorsky., Urvashi Roongta., Amrita Kamath., Punit Marathe., Sunanda A. Ranadive., John S. Sack., John S. Tokarski., Nikola P. Pavletich., Francis Y. F. Lee., Kevin R. Webster and S. David Kimball. (2002). N-(Cycloalkylamino)acyl-2-aminothiazole Inhibitors of Cyclin-Dependent Kinase 2. N-[5-[[[5-(1,1-Dimethylethyl)-2-oxazolyl]methyl]thio]-2-thiazolyl]-4-piperidinecarboxamide (BMS-387032), a Highly Efficacious and Selective Antitumor Agent. J. Med. Chem. 47, 1719-1728.